Ford to Move Some Lincoln Production From China to U.S. in 2030 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Add as a preferred source on Google
DALLAS and FORT WORTH, Texas, Feb. 28, 2017 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin Garg, Ph.D., president and chief executive officer, will present a company overview at the upcoming Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET in Boston, MA.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected]
